LENZ Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (21 May 2024 @ 16:00):

LENZ Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia...

Stats
Today's Volume	189 256
Average Volume	287 672
Market Cap	475.94M
EPS	$0 ( 2024-05-09 )
Next earnings date	( $-0.420 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0520 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-14	Chevallard Daniel R.	Buy	3 188	Common Stock
2024-05-13	Mccollum James W	Buy	31 332	Common Stock
2024-03-21	Alpha Wave Ventures Gp, Ltd	Buy	0	Common Stock, par value $0.00001 per share
2024-03-21	Ra Capital Management, L.p.	Buy	933 038	Common Stock
2024-03-21	Ra Capital Management, L.p.	Buy	2 386 301	Common Stock

INSIDER POWER
98.20
Last 38 transactions
Buy: 7 772 479 \| Sell: 70 534

Volume Correlation

Long: 0.20 (neutral)

Short: -0.19 (neutral)

Signal:(49.83) Neutral

LENZ Therapeutics, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

LENZ Therapeutics, Inc. Correlation - Currency/Commodity

-0.17
( neutral )

-0.74
( moderate negative )

0.00
( neutral )

-0.77
( moderate negative )

0.63
( weak )

0.84
( strong )

LENZ Therapeutics, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-2.41M (0.00 %)
EPS:	$-15.30

FY	2023
Revenue:	$0
Gross Profit:	$-2.41M (0.00 %)
EPS:	$-15.30

Financial Reports:

No articles found.

LENZ Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.